For years, the standard of care for advanced prostate cancer has relied on a fundamental biological truth: these tumors are typically fuel-dependent, craving male sex hormones known as androgens to grow. By lowering these hormone levels through surgery or medication—a process known as androgen deprivation therapy (ADT)—doctors can often shrink tumors and extend survival for significant periods.
However, for many patients, this success is temporary. The cancer eventually finds a workaround, evolving into what clinicians call castration-resistant prostate cancer (CRPC). In these cases, the tumor learns to grow despite low androgen levels, rendering standard treatments ineffective and leaving patients with fewer options.
New research led by Professor Yosef Yarden of the Weizmann Institute of Science suggests that this resistance isn’t random. According to a study published in EMBO Molecular Medicine, a common genetic alteration—a fusion of two genes—acts as a biological “backdoor,” allowing tumors to stop relying on androgens and instead switch their fuel source to cortisol, the body’s primary stress hormone.
As a physician, I find this discovery particularly critical because it doesn’t just offer a new target for treatment. it identifies a potential danger in how we currently manage advanced cancer patients. Because steroids are frequently prescribed to manage the side effects of cancer treatment or to reduce inflammation, we may have been inadvertently feeding the extremely tumors we were trying to starve.
The Cortisol Switch: How Tumors Bypass Therapy
The research team, led by Dr. Arunachalam Sekar and Prof. Yarden, discovered that a specific gene fusion occurs in roughly half of all prostate cancers. This fusion creates a hybrid protein that alters the cell’s internal signaling. Under normal conditions, androgen signaling suppresses the pathways that cortisol uses to promote growth. But when a patient undergoes androgen deprivation therapy, that suppression vanishes.
In tumors carrying this gene fusion, the resulting hybrid protein partners with the glucocorticoid receptor (the receptor for cortisol). This partnership activates cancer-promoting genes, effectively mimicking the growth signals that androgens once provided. The tumor doesn’t “fix” the androgen problem; it simply switches its dependence to a different steroid hormone that the body continues to produce.
This mechanism explains why some patients respond brilliantly to initial hormone therapy only to see their disease return aggressively. The “switch” to cortisol provides a survival mechanism that allows the cancer to thrive even in a low-androgen environment.
A Warning on Steroid Use in Advanced Cancer
One of the most urgent takeaways from the Weizmann Institute study is the clinical implication of steroid administration. Glucocorticoids (synthetic versions of cortisol) are common in oncology settings, often used to treat nausea, allergic reactions, or to improve the appetite and well-being of patients with advanced disease.
The study indicates that for patients whose tumors possess this specific gene fusion, these steroid drugs may actually accelerate tumor growth. By providing more “fuel” to the glucocorticoid receptors, the therapy may be inadvertently promoting the progression of the disease. This suggests a pressing need for molecular screening to identify which patients carry the fusion before steroids are prescribed.
Moving Toward Combination Therapy
The research team didn’t stop at identifying the problem; they tested a potential solution. Using mouse models of human prostate cancer, the researchers experimented with a dual-pronged attack: blocking both androgen signaling and cortisol activity simultaneously.
The results were significant. While blocking androgens alone eventually led to resistance, and blocking cortisol alone had limited impact, the combination therapy suppressed tumor growth over time and extended survival. By closing both the “front door” (androgens) and the “backdoor” (cortisol), the researchers were able to keep the cancer in check more effectively.
The following table summarizes the shift in treatment strategy proposed by the research:
| Treatment Approach | Primary Target | Outcome in Fusion-Positive Tumors |
|---|---|---|
| Standard ADT | Androgen Signaling | Initial response, followed by cortisol-driven resistance |
| Steroid Therapy | Inflammation/Symptoms | Potential acceleration of tumor growth |
| Combination Therapy | Androgen + Cortisol Pathways | Suppressed tumor growth and extended survival |
The Path to Clinical Application
While the results in animal models are promising, the transition to human patients requires careful navigation. The study was supported by data from human patients obtained through a collaboration with the National Cancer Institute (NCI) in Bethesda, Maryland, which helps ground these findings in human biology. However, the next step involves validating these findings in larger clinical cohorts to determine exactly how many patients would benefit from cortisol-blocking agents.
The challenge for oncologists will be balancing the benefits of glucocorticoids—which can significantly improve a patient’s quality of life—against the risk of promoting tumor growth. The goal is a precision medicine approach: testing for the gene fusion marker first, then tailoring the hormone therapy accordingly.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their oncologist or healthcare provider before making any changes to their treatment plan.
The research community now looks toward the development of targeted clinical trials to test the efficacy of glucocorticoid receptor inhibitors in combination with standard anti-androgen therapies. Further updates on these trials are expected as the Weizmann Institute and its collaborators move toward human validation phases.
Do you or a loved one navigate the complexities of prostate cancer treatment? Share your thoughts or questions in the comments below.
